Navigation Links
GranuFlo Lawsuits News: Missouri Federal Court Returns Multi-Plaintiff Case to State Court, Rottenstein Law Group LLP Reports
Date:1/15/2014

(PRWEB) January 15, 2014

A lawsuit against Fresenius Medical Care, the manufacturer of GranuFlo, brought by 74 plaintiffs (or their estates, in the cases of those who died from their injuries), has been returned to state court by the federal court to which the defendant had previously removed the matter, according to documents in Agnew v. Fresenius (no. 4:13-2468; United States District Court for the Eastern District of Missouri). A magistrate judge ruled that the federal court does not have proper jurisdiction to hear the case, according to the January 9 remand order.

The plaintiffs, from 27 different states, seek monetary relief for injuries or deaths allegedly resulting from use of GranuFlo dialysis products designed, manufactured, tested, promoted, and sold by Fresenius, according to documents filed in the case. The Rottenstein Law Group LLP, which represents clients in GranuFlo dialysis injury lawsuits, maintains a website at http://www.granuflo-lawsuit.net that features information on GranuFlo side effects and lawsuits.

In June 2012 the U.S. Food and Drug Administration issued a Class 1 Recall after learning about the alleged adverse side effects involving the heart.* The FDA had originally approved the drug for distribution in 2003.

“That the resolution of this matter was delayed by a procedural tacticc ultimately undone by the federal court is unfortunate,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP., ”but at least now, with the remand, the Missouri state court can get to the substance of the case.”

The Rottenstein Law Group LLP encourages those who believe they have suffered from the alleged side effects of GranuFlo to read the frequently asked questions and answers about the drug to learn more about its side effects and how to file a lawsuit.

*fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm305630.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016

Read the full story at http://www.prweb.com/releases/2014/01/prweb11490108.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
2. GranuFlo Recall Website Launched By Hissey Kientz, LLP Law Firm
3. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
4. GranuFlo Lawsuits Filed in Wake of GranuFlo and NaturaLyte Recall Mount in State and Federal Courts, Bernstein Liebhard LLP Reports
5. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
6. New Granuflo Cardiac Arrest Lawsuit: Now, AttorneyOne Can Provide Advice
7. GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Growing Litigation Surrounding GranuFlo Recall
8. Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama
9. GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
10. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard Notes Issuance of New Order in Federal GranuFlo Recall Litigation
11. GranuFlo Lawsuit News: W.Va. Man’s Lawsuit Goes to Federal Court, Rottenstein Law Group LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... The National Campaign to Prevent ... Access to Contraception for Women Servicemembers and Dependents Act of 2017. The bill, ... help to ensure that all members of the Armed Forces receive high quality ...
(Date:4/28/2017)... ... 28, 2017 , ... Somnoware, a leading provider of digital ... enables sleep physicians to create and edit their interpretation reports. This solution greatly ... familiar interface that does not require additional training to use. It also allows ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it also ... hours without sleep can compromise motor reaction time, which can increase the risk of having ... sharing the following tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces the ... instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ... hour rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and ... more adverse experiences than children in the general population. That’s because foster care ... or other family challenges. While no fault of their own, youth who have ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... AMSTERDAM , April 20, 2017  AbbVie ... that 99 percent (n=145/146) of chronic hepatitis C ... 4, 5 or 6 and compensated cirrhosis (Child-Pugh ... post-treatment (SVR 12 ) with its investigational, pan-genotypic ... rates were seen following 12 weeks of ...
Breaking Medicine Technology: